This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Inoue, S. Articles by Cohen, G. M. Search for Related Content PubMed PubMed Citation Articles by Inoue, S. Articles by Cohen, G. M.

Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis

¹ Medical Research Council Toxicology Unit, University of Leicester, Leicester, United Kingdom; and ² Istituto Pasteur, Fondazione Cenci-Bolognetti, Dipartimento di Studi Farmaceutici, Universita degli Studi di Roma "La Sapienza," Rome, Italy

Requests for reprints: Gerald M. Cohen, Medical Research Council Toxicology Unit, Hodgkin Building, University of Leicester, P.O. Box 138, Lancaster Road, Leicester LE1 9HN, United Kingdom. Phone: 44-116-2525601; Fax: 44-116-2525616; E-mail: gmc2{at}le.ac.uk.

From work done largely on derived cell lines, it has been suggested that tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) might be a therapeutic target for many forms of malignancy. However, use of primary tumor cells, including chronic lymphocytic leukemic (CLL) cells, has shown inherent resistance to TRAIL. Although the molecular basis for this resistance remains unknown, treatment with histone deacetylase inhibitors (HDACi) often sensitizes resistant cells to TRAIL-induced apoptosis. We used structurally diverse HDACi to ascertain which HDAC needs to be inhibited for the sensitization. Inhibition of HDAC class I but not class II is required for sensitization to TRAIL-induced apoptosis of CLL cells and various cell lines. Using different HDACi together with small interfering RNA for HDAC1, HDAC2, HDAC3, and HDAC6, we report that inhibition of HDAC1 and HDAC2 but not HDAC3, HDAC6, and HDAC8 are primarily responsible for sensitization to TRAIL-induced apoptosis. Based on these data and our previous studies, we propose that a clinical trial in CLL is warranted using a combination of a selective HDACi that inhibits HDAC1 and/or HDAC2 together with a form of TRAIL that signals through TRAIL receptor 1. (Cancer Res 2006; 66(13): 6785-92)

This article has been cited by other articles:

				G. Ishdorj, B. A. Graham, X. Hu, J. Chen, J. B. Johnston, X. Fang, and S. B. Gibson Lysophosphatidic Acid Protects Cancer Cells from Histone Deacetylase (HDAC) Inhibitor-induced Apoptosis through Activation of HDAC J. Biol. Chem., June 13, 2008; 283(24): 16818 - 16829. [Abstract] [Full Text] [PDF]

				H. Su, L. Altucci, and Q. You Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors Mol. Cancer Ther., May 1, 2008; 7(5): 1007 - 1012. [Abstract] [Full Text] [PDF]

				F.-T. Liu, S. G. Agrawal, J. G. Gribben, H. Ye, M.-Q. Du, A. C. Newland, and L. Jia Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL Blood, March 1, 2008; 111(5): 2797 - 2805. [Abstract] [Full Text] [PDF]

				M. J.S. Dyer, M. MacFarlane, and G. M. Cohen Barriers to Effective TRAIL-Targeted Therapy of Malignancy J. Clin. Oncol., October 1, 2007; 25(28): 4505 - 4506. [Full Text] [PDF]

				D. A. West, D. M. Lucas, M. E. Davis, M. D. De Lay, A. J. Johnson, S. E. Guster, M. A. Freitas, M. R. Parthun, D. Wang, S. K. Kulp, et al. The Novel Histone Deacetylase Inhibitor OSU-HDAC42 Has Class I and II Histone Deacetylase (HDAC) Inhibitory Activity and Represents a Novel Therapy for Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 2807 - 2807. [Abstract] [PDF]